- Home
- PRSO vs RDHL Comparison
PRSO vs RDHL Comparison
Compare PRSO & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSO
- RDHL
- Stock Information
- Founded
- PRSO 2008
- RDHL 2009
- Country
- PRSO United States
- RDHL Israel
- Employees
- PRSO N/A
- RDHL N/A
- Industry
- PRSO Semiconductors
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- PRSO Technology
- RDHL Health Care
- Exchange
- PRSO Nasdaq
- RDHL Nasdaq
- Market Cap
- PRSO 4.3M
- RDHL 3.8M
- IPO Year
- PRSO 2001
- RDHL N/A
- Fundamental
- Price
- PRSO $0.97
- RDHL $1.80
- Analyst Decision
- PRSO Strong Buy
- RDHL
- Analyst Count
- PRSO 2
- RDHL 0
- Target Price
- PRSO $3.38
- RDHL N/A
- AVG Volume (30 Days)
- PRSO 186.2K
- RDHL 219.3K
- Earning Date
- PRSO 05-12-2025
- RDHL 04-10-2025
- Dividend Yield
- PRSO N/A
- RDHL N/A
- EPS Growth
- PRSO N/A
- RDHL N/A
- EPS
- PRSO N/A
- RDHL N/A
- Revenue
- PRSO $15,626,000.00
- RDHL $8,042,999.00
- Revenue This Year
- PRSO $3.96
- RDHL $381.91
- Revenue Next Year
- PRSO $36.80
- RDHL N/A
- P/E Ratio
- PRSO N/A
- RDHL N/A
- Revenue Growth
- PRSO 35.50
- RDHL 23.17
- 52 Week Low
- PRSO $0.52
- RDHL $1.71
- 52 Week High
- PRSO $2.34
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- PRSO 56.62
- RDHL 36.06
- Support Level
- PRSO $0.86
- RDHL $1.73
- Resistance Level
- PRSO $1.03
- RDHL $1.93
- Average True Range (ATR)
- PRSO 0.08
- RDHL 0.10
- MACD
- PRSO 0.00
- RDHL 0.02
- Stochastic Oscillator
- PRSO 59.37
- RDHL 28.12
About PRSO Peraso Inc.
Peraso Inc is a fabless semiconductor company focused on the development and sale of: i) millimeter wavelength wireless technology, or mmWave, semiconductor devices and antenna modules based on its proprietary semiconductor devices and ii) performance of non-recurring engineering, or NRE, services and licensing of intellectual property, or IP. The company's primary focus is the development of mmWave, which is generally described as the frequency band from 24 Gigahertz, or GHz, to 300 GHz. Geographically the company generates revenue from the United States, Hong Kong, Taiwan, and the Rest of the World.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.